Clinical Trial Update: Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins

View source ↗

Summary

A clinical trial update describes evaluating pHA hemoperfusion plus hemodialysis to reduce protein-bound uremic toxins in people with end-stage renal disease on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Snippet

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: End Stage Renal Disease on Dialysis | Status: RECRUITING